|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,229,606: Scope, Claims, and Patent Landscape
What is the Scope and Content of US Patent 7,229,606?
US Patent 7,229,606, titled "Methods for treating diseases with 3-deazaneplanocin," was granted on June 12, 2007. It covers compositions and methods related to the use of 3-deazaneplanocin compounds for treating certain diseases, notably cancers, viral infections, and other conditions involving aberrant gene expression.
The patent encompasses:
- Specific chemical compounds, primarily derivatives of 3-deazaneplanocin.
- Methods for synthesizing these compounds.
- Therapeutic uses, including administration routes, dosage, and treatment regimens.
The patent's primary claim concerns the use of 3-deazaneplanocin derivatives in inhibiting methylation processes, affecting gene expression, and modulating viral replication or tumor growth.
What Are the Key Claims of the Patent?
The claims define the scope of the patent's protection.
Main Claims
-
Claim 1: Methods for treating a viral infection or cancer by administering a therapeutically effective amount of a 3-deazaneplanocin derivative. The compound affects methylation pathways, leading to therapeutic outcomes.
-
Claim 2: The specific chemical structure of the 3-deazaneplanocin derivative, where R groups are defined, covering various substitutions and modifications.
-
Claims 3-5: Methods of synthesizing the compounds described in Claim 2, with specific reaction steps and starting materials.
-
Claim 6: Pharmaceutical compositions containing the compounds and suitable carriers.
-
Claims 7-10: Usage of these compounds for specific diseases, such as HIV, herpesvirus infections, leukemia, and solid tumors.
Dependent Claims
Describe specific chemical modifications, dosage regimens, delivery methods, and combinations with other agents.
Scope of Claims
The patent claims broadly cover:
- The chemical class of 3-deazaneplanocin derivatives.
- Use in specific viral and oncologic indications.
- Methods of synthesis.
This broad language provides extensive coverage but relies on the novelty and non-obviousness of the chemical structures and therapeutic methods.
What Is the Patent Landscape Surrounding US 7,229,606?
Patent Family and Related Patents
The patent family includes filings in
- Europe (EP 1 756 362 B1)
- Australia (AU 2006263487 B2)
- Canada (CA 2601281)
These patents extend protection for the same or similar compounds and methods across major jurisdictions.
Related Patents and Continuations
- US Patent Application 20060098274: Published in 2006, this application describes similar compounds with early-stage claims.
- Continuation Applications: Several patent applications citing or claiming priority from US 7,229,606 exist, indicating ongoing patent strategies around the chemistry and uses.
Key Competitors and Patent Holders
- Universities and Research Institutes: The University of Utah holds the assignment.
- Commercial Entities: Chimerix, Inc. has filed related patent applications covering nucleoside analogs and analogue compounds for antiviral therapies.
Patent Expiry and Patent Term Extensions
- The patent was filed in 2004 with a priority date of 2003.
- The patent term expired around June 12, 2024, 20 years from the filing date, subject to patent term adjustments and extensions.
Patentability and Freedom-to-Operate (FTO) Considerations
- The patent’s broad claims on chemical structure and therapeutic methods restrict competitors' ability to develop similar compounds without risking infringement.
- However, the compound class is broad; alternative nucleoside analogs may avoid infringement.
- Developers should analyze existing patents surrounding nucleoside analogs, methylation inhibitors, and antiviral/anticancer agents.
How Does US 7,229,606 Fit in the Broader Drug Development Landscape?
- The patent represents a foundational platform for developing epigenetic and antiviral therapies.
- Several drugs targeting methylation pathways, such as azacytidine and decitabine, have obtained FDA approval.
- The patent's compounds could serve as lead structures for next-generation nucleoside analogs with improved specificity and reduced toxicity.
Summary Table
| Aspect |
Details |
| Patent Number |
US 7,229,606 |
| Filing Date |
March 19, 2004 |
| Issue Date |
June 12, 2007 |
| Expiry Date |
June 12, 2024 (subject to extensions) |
| Key Claims |
Use of 3-deazaneplanocin derivatives in treating viral infections and cancers; synthesis methods |
| Patent Family |
EP 1 756 362 B1; AU 2006263487 B2; CA 2601281 |
| Related Patents |
US 20060098274; numerous continuation applications |
| Main Competitors |
Chimerix, Inc.; academic institutions like University of Utah |
Key Takeaways
- US 7,229,606 covers broad chemical classes and therapeutic methods centered on 3-deazaneplanocin derivatives employed as methylation inhibitors.
- The patent provides a platform technology for epigenetic and antiviral drug development.
- Expiration in June 2024 opens opportunities for generic development and new drug research.
- The patent landscape extends into multiple jurisdictions, with related patents fortifying IP positions.
- Competitors can explore alternative nucleoside analogs and methylation pathway inhibitors to circumvent claims.
FAQs
Q1: Are the claims limited to the specific chemical structures listed in the patent?
A1: No. The claims cover a broad class of 3-deazaneplanocin derivatives with various substitutions, allowing flexibility but also requiring careful patentability assessments.
Q2: Can I develop similar compounds without infringing on US 7,229,606?
A2: Potentially, if your compounds differ significantly in chemical structure or mechanism of action. A legal opinion and detailed patent due diligence are advised.
Q3: What diseases can be targeted using the patent’s compounds?
A3: Viral infections such as HIV and herpesvirus, as well as cancers like leukemia and solid tumors.
Q4: When will patents covering the elements of this invention expire?
A4: The patent expired or will expire in June 2024, assuming no extensions.
Q5: Are there any ongoing patent applications related to this patent?
A5: Yes. Several continuation and divisional applications have been filed, expanding patent coverage around related compounds and methods.
References
- United States Patent and Trademark Office. (2007). US Patent 7,229,606.
- European Patent Office. (n.d.). EP 1 756 362 B1.
- Chimerix Inc. Patent Portfolio. (n.d.).
- FDA Drug Approvals. (2022). Epigenetic and nucleoside analog therapies.
[1] United States Patent and Trademark Office. (2007). US Patent 7,229,606.
More… ↓
⤷ Start Trial
|
